Interferon-Free Strategies without a Nucleoside/Nucleotide Analogue

 

 Buy Article Permissions and Reprints

Abstract

The identification of viral and host factors involved in hepatitis C virus (HCV) replication was a key prerequisite for the discovery and further exploration of antiviral drug targets. As of today, numerous direct-acting antiviral agents (DAAs), as well as host-targeting agents (HTAs), have been developed and entered clinical testing. The goal to omit pegylated interferon due to its unfavorable side-effect profile from novel HCV therapeutic approaches led to an expedited design and competitive conduct of DAA combination trials striving for easily applicable, all-oral HCV treatments. Approval of several interferon-free regimens is awaited in the near future (2014/2015). Results of different DAA combination trials (without nucleos(t)ide polymerase inhibitors) and trials involving HTAs are reviewed herein.

• References

• 1 Lohmann V, Körner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285 (5424) 110-113
  CrossrefPubMedGoogle Scholar
• 2 Lohmann V, Bartenschlager R. On the history of hepatitis C virus cell culture systems. J Med Chem 2013; ; In press
  PubMedGoogle Scholar
• 3 Bartenschlager R, Lohmann V, Penin F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol 2013; 11 (7) 482-496
  CrossrefPubMedGoogle Scholar
• 4 Lange CM, Jacobson IM, Rice CM, Zeuzem S. Emerging therapies for the treatment of hepatitis C. EMBO. Mol Med 2013; ; In press
  PubMedGoogle Scholar
• 5 Manns MP, von Hahn T. Novel therapies for hepatitis C - one pill fits all?. Nat Rev Drug Discov 2013; 12 (8) 595-610
  CrossrefPubMedGoogle Scholar
• 6 Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57 (4) 1333-1342
  CrossrefPubMedGoogle Scholar
• 7 Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Ward JW. Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention. Ann Intern Med 2012; 157 (11) 817-822
  CrossrefPubMedGoogle Scholar
• 8 Moyer VA ; U.S. Preventive Services Task Force. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013; 159 (5) 349-357
  CrossrefPubMedGoogle Scholar
• 9 Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med 2013; 19 (7) 850-858
  CrossrefPubMedGoogle Scholar
• 10 Jacobson IM, McHutchison JG, Dusheiko G , et al; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364 (25) 2405-2416
  CrossrefPubMedGoogle Scholar
• 11 Zeuzem S, Andreone P, Pol S , et al; REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364 (25) 2417-2428
  CrossrefPubMedGoogle Scholar
• 12 Poordad F, McCone Jr J, Bacon BR , et al; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364 (13) 1195-1206
  CrossrefPubMedGoogle Scholar
• 13 Bacon BR, Gordon SC, Lawitz E , et al; HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364 (13) 1207-1217
  CrossrefPubMedGoogle Scholar
• 14 Lok AS, Gardiner DF, Lawitz E , et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366 (3) 216-224
  CrossrefPubMedGoogle Scholar
• 15 Simmonds P, Bukh J, Combet C , et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42 (4) 962-973
  CrossrefPubMedGoogle Scholar
• 16 Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007; 5 (6) 453-463
  CrossrefPubMedGoogle Scholar
• 17 Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010; 138 (2) 447-462
  CrossrefPubMedGoogle Scholar
• 18 Vermehren J, Sarrazin C. The role of resistance in HCV treatment. Best Pract Res Clin Gastroenterol 2012; 26 (4) 487-503
  CrossrefPubMedGoogle Scholar
• 19 Gerber L, Welzel TM, Zeuzem S. New therapeutic strategies in HCV: polymerase inhibitors. Liver Int 2013; 33 (Suppl. 01) 85-92
  CrossrefPubMedGoogle Scholar
• 20 Pockros PJ. Nucleoside/nucleotide analogue polymerase inhibitors in development. Clin Liver Dis 2013; 17 (1) 105-110
  CrossrefPubMedGoogle Scholar
• 21 Feld J. IFN-free strategies with a nucleoside/nucleotide analogue. Semin Liver Dis 2014; 34 (1) 37-46
  Article in Thieme ConnectPubMedGoogle Scholar
• 22 Pockros PJ. Non-nucleoside analogue polymerase inhibitors in development. Clin Liver Dis 2013; 17 (1) 123-128
  CrossrefPubMedGoogle Scholar
• 23 Ciesek S, von Hahn T, Manns MP. Second-wave protease inhibitors: choosing an heir. Clin Liver Dis 2011; 15 (3) 597-609
  CrossrefPubMedGoogle Scholar
• 24 Clark VC, Peter JA, Nelson DR. New therapeutic strategies in HCV: second-generation protease inhibitors. Liver Int 2013; 33 (Suppl. 01) 80-84
  CrossrefPubMedGoogle Scholar
• 25 Summa V, Ludmerer SW, McCauley JA , et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother 2012; 56 (8) 4161-4167
  CrossrefPubMedGoogle Scholar
• 26 Huang M, Podos S, Patel D , et al. ACH-2684: HCV NS3 protease inhibitor with a potent activity against multiple genotypes and known resistant variants. Hepatology 2010; 52 (S1): 1204A
  PubMedGoogle Scholar
• 27 Coburn CA, Meinke PT, Chang W , et al. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. ChemMedChem 2013; 8 (12) 1930-1940 [Epub ahead of print]
  CrossrefPubMedGoogle Scholar
• 28 Achillion. ACH-3102 HCV NS5A inhibitor. Available at: http://www.achillion.com/ACH_3102 . Accessed November 18, 2013
  PubMedGoogle Scholar
• 29 Zeuzem S, Soriano V, Asselah T , et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 2013; 369 (7) 630-639
  CrossrefPubMedGoogle Scholar
• 30 Dufour JF, Buti M, Soriano V , et al. Interferon-Free Treatment with Faldaprevir, Deleobuvir (BI 207127) and RBV in SOUND-C3: 95% SVR12 in HCV-GT 1b. Hepatology 2013; 58 (4) 139A [1102]
  PubMedGoogle Scholar
• 31 ClinicalTrials.gov. IFN-free combination therapy in HCV-infected patients treatment-naive:HCVerso1. Available at: http://www.clinicaltrials.gov/ct2/results?term=HCVerso1&Search=Search . Accessed November 18, 2013
  PubMedGoogle Scholar
• 32 ClinicalTrials.gov. Phase 3 study of BI 207127 in combination with faldaprevir and ribavirin for treatment of patients with hepatitis C infection, including patients who are not eligible to receive peginterferon: HCVerso2. Available at: http://www.clinicaltrials.gov/ct2/results?term=HCVerso2&Search=Search . Accessed November 18, 2013
  PubMedGoogle Scholar
• 33 ClinicalTrials.gov. BI 207127 / faldaprevir combination therapy in hepatic impairment (Child-Pugh B) patients with genotype 1b chronic hepatitis C infection: HCVerso3. Available at: http://www.clinicaltrials.gov/ct2/results?term=hcverso3&Search=Search . Accessed November 18, 2013
  PubMedGoogle Scholar
• 34 Lawitz E, Poordad F, Kowdley KV , et al. A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1. J Hepatol 2013; 59 (1) 18-23
  CrossrefPubMedGoogle Scholar
• 35 Poordad F, Lawitz E, Kowdley KV , et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013; 368 (1) 45-53
  CrossrefPubMedGoogle Scholar
• 36 Kowdley KV, Lawitz E, Poordad F , et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 2014; 16; 370 (3) 222-232
  CrossrefPubMedGoogle Scholar
• 37 Jacobsen IM, Sulkowski MS, Gane EJ , et al. VX-222, Telaprevir, and ribavirin in treatment naïve patients with genotype 1 chronic hepatitis C: results from the ZENITH study interferon-free regimen. Hepatology 2012; 56 (4) 87A [231]
  PubMedGoogle Scholar
• 38 Jensen DM, Brunda M, Elston R , et al. Interferon-free regimen containing setrobuvir (STV) in combination with ritonavir-boosted danoprevir (DNVr) and ribavirin (R) with or without mericitabine (MCB) in HCV genotype (G)1 treatment-naive patients: interim SVR4 results from the ANNAPURNA study. Hepatology 2013; 58 (4) 139A [1098]
  PubMedGoogle Scholar
• 39 ClinicalTrials.gov. A study to evaluate the safety, tolerability, and effectiveness of a 12-week combination therapy of TMC647055 and TMC435 with and without GSK23336805 with a pharmacokinetic enhancer with and without ribavirin in patients infected with chronic genotype 1 hepatitis C virus. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01724086?term=tmc435&rank=26 . Accessed November 18, 2013
  PubMedGoogle Scholar
• 40 Suzuki Y, Ikeda K, Suzuki F , et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 2013; 58 (4) 655-662
  CrossrefPubMedGoogle Scholar
• 41 Chayama K, Takahashi S, Toyota J , et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012; 55 (3) 742-748
  CrossrefPubMedGoogle Scholar
• 42 Lok AS, Gardiner DF, Hézode C, Lawitz EJ , et al. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol 2014; Mar; 60 (3) 490-499
  CrossrefPubMedGoogle Scholar
• 43 Bronowicki JP, Pol S, Thuluvath PJ , et al. BMS-650032, an NS3 inhibitor, in combination with peginterferon alfa-2a and ribavirin in treatment-naive subjects with genotype 1 chronic hepatitis C infection. [abstract] J Hepatol 2011; 54: S472 . [1195]
  PubMedGoogle Scholar
• 44 Chayama K, Suzuki Y, Ikeda K , et al. All-oral combination of daclatasvir plus asunaprevir in interferon ineligible naive/intolerant and nonresponder Japanese patients chronically infected with HCV Genotype 1b: results from a phase 3 trial. Hepatology 2013; 58 (4) 86A [211]
  PubMedGoogle Scholar
• 45 ClinicalTrials.gov. Phase III Hallmark DUAL: ASV + DCV (nulls/partials, intolerants/ineligibles. naives). Available at: http://www.clinicaltrials.gov/ct2/show/NCT01581203?term=hallmark+dual&rank=1 . Accessed November 18, 2013
  PubMedGoogle Scholar
• 46 ClinicalTrials.gov. Study of daclatasvir and TMC435 for subjects with genotype 1 chronic hepatitis C. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01628692?term=tmc435+daclatasvir&rank=1 . Accessed on November 18, 2013
  PubMedGoogle Scholar
• 47 Lawitz E, Hezode C, Varunok P , et al. Interferon- and Ribavirin-free regimen of ABT-450/r + ABT-267 in HCV genotype 1b-infected treatment naive patients and prior null responders. Hepatology 2013; 58 (4) 62A [75]
  PubMedGoogle Scholar
• 48 Lawitz E, Vierling JM, Murillo A , et al. High efficacy and safety of the all-oral combination regimen, MK-5172/MK-8742.  ± RBV for 12 weeks in HCV genotype 1 infected patients: the C-WORTHY study. Hepatology 2013; 58 (4) 62A [76]
  PubMedGoogle Scholar
• 49 Achillion. Achillion provides update on sovaprevir development program. Available at: http://ir.achillion.com/releasedetail.cfm?ReleaseID=774834 . Accessed November 18, 2013
  PubMedGoogle Scholar
• 50 Lalezari JP, Holland L, Glutzer E , et al. Rapid and consistent virologic responses in a phase 2 trial of a new all-oral combination of faldaprevir, deleobuvir, and PPI-668, with and without ribavirin, in patients with HCV genotype-1a infection. Hepatology 2013; 58 (4) [LB-20]
  PubMedGoogle Scholar
• 51 Everson GT, Sims KD, Rodriguez-Torres M , et al. Efficacy of an Interferon- and Ribavirin-free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-naïve Patients with HCV Genotype 1 Infection. Gastroenterology 2014; 146 (2) 420-429
  CrossrefPubMedGoogle Scholar
• 52 Everson GT, Sims KD, Thuluvath PJ , et al. Phase 2b study of the interferon-free and ribavirin-free combination of daclatasvir, asunaprevir, and BMS-791325 for 12 weeks in treatment-naïve patients with chonic HCV genotype 1 infection. Hepatology 2013; 58 (4) [LB-1]
  PubMedGoogle Scholar
• 53 Cohen DE, Xie W, Larsen L , et al. Safety of ribavirin containing regimens of ABT-450/r, ABT-333, and ABT-267 for the treatment of HCV genotype 1 infection and efficacy in subjects with ribavirin dose reductions. Hepatology 2013; 58 (4) 140A [1118]
  PubMedGoogle Scholar
• 54 ClinicalTrials.gov. A study to evaluate chronic hepatitis C infection. Available at: http://www.clinicaltrials.gov/ct2/results?term=sapphire-I&Search=Search . Accessed November 18, 2013
  PubMedGoogle Scholar
• 55 ClinicalTrials.gov. A study to evaluate chronic hepatitis C infection in treatment experienced adults. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01715415?term=sapphire-II&rank=1 . Accessed November 18, 2013
  PubMedGoogle Scholar
• 56 ClinicalTrials.gov. A study to evaluate the safety and effect of ABT-450, ritonavir and ABT-267 (ABT-450/r/ABT-267) and ABT-333 coadministered with ribavirin (RBV) in hepatitis C virus (HCV) genotype 1-infected adults with compensated cirrhosis (TURQUOISE-II). Available at: http://www.clinicaltrials.gov/ct2/show/NCT01704755?term=turquoise&rank=1 . Accessed November 18, 2013
  PubMedGoogle Scholar
• 57 ClinicalTrials.gov. AbbVie Demonstrates 96 percent SVR(12) in its Phase III Study of Treatment-Experienced Patients with Genotype 1 Hepatitis C. Available at: http://abbvie.mediaroom.com/index.php?year=2013&s=20295 . Accessed December 27, 2013
  PubMedGoogle Scholar
• 58 ClinicalTrials.gov. A study to evaluate the safety and effect of the experimental drugs ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in people with chronic hepatitis C (PEARL-II). Available at: http://www.clinicaltrials.gov/ct2/show/NCT01674725?term=PEARL-II&rank=1 . Accessed November 18, 2013
  PubMedGoogle Scholar
• 59 ClinicalTrials.gov. A study to evaluate chronic hepatitis C infection in adults with genotype 1b infection (PEARL-III). Available at: http://www.clinicaltrials.gov/ct2/show/NCT01767116?term=Pearl-III&rank=1 . Accessed November 18, 2013
  PubMedGoogle Scholar
• 60 ClinicalTrials.gov. A study to evaluate chronic hepatitis C infection in adults with genotype 1a infection. Available at: http://www.clinicaltrials.gov/ct2/results?term=Pearl-IV&Search=Search . Accessed November 18, 2013
  PubMedGoogle Scholar
• 61 Toyota J, Ozeki I, Karino Y , et al. Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b. J Viral Hepat 2013; 20 (3) 167-173
  CrossrefPubMedGoogle Scholar
• 62 Gane EJ, Ari ZB, Mollison L , et al. Efficacy and safety of an interferon-free regimen of MK-5172 + Ribavirin for 12 weeks or 24 weeks in treatment naive, non cirrhotic subjects with HCV GT1 infection: the C-Spirit study. Hepatology 2013; 58 (4) 140A [1110]
  PubMedGoogle Scholar
• 63 Baugh JM, Garcia-Rivera JA, Gallay PA. Host-targeting agents in the treatment of hepatitis C: a beginning and an end?. Antiviral Res 2013; 100 (2) 555-561
  CrossrefPubMedGoogle Scholar
• 64 Zeisel MB, Lupberger J, Fofana I, Baumert TF. Host-targeting agents for prevention and treatment of chronic hepatitis C - perspectives and challenges. J Hepatol 2013; 58 (2) 375-384
  CrossrefPubMedGoogle Scholar
• 65 Meuleman P, Hesselgesser J, Paulson M , et al. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology 2008; 48 (6) 1761-1768
  CrossrefPubMedGoogle Scholar
• 66 Meuleman P, Catanese MT, Verhoye L , et al. A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. Hepatology 2012; 55 (2) 364-372
  CrossrefPubMedGoogle Scholar
• 67 Lacek K, Vercauteren K, Grzyb K , et al. Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. J Hepatol 2012; 57 (1) 17-23
  CrossrefPubMedGoogle Scholar
• 68 Lupberger J, Zeisel MB, Xiao F , et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 2011; 17 (5) 589-595
  CrossrefPubMedGoogle Scholar
• 69 Sainz Jr B, Barretto N, Martin DN , et al. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med 2012; 18 (2) 281-285
  CrossrefPubMedGoogle Scholar
• 70 Sulkowski MS, Kang M, Matining R , et al. AIDS Clinical Trials Group A5277 Protocol Team. Safety and Antiviral Activity of the HCV Entry Inhibitor ITX5061 in Treatment-Naive HCV-Infected Adults: A Randomized, Double-Blind, Phase 1b Study. J Infect Dis 2014; Mar; 209 (5) 658-667
  CrossrefPubMedGoogle Scholar
• 71 Chen K, Rajewsky N. The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet 2007; 8 (2) 93-103
  PubMedGoogle Scholar
• 72 Thibault PA, Wilson JA. Targeting miRNAs to treat Hepatitis C Virus infections and liver pathology: Inhibiting the virus and altering the host. Pharmacol Res 2013; 75: 48-59
  CrossrefPubMedGoogle Scholar
• 73 Janssen HL, Reesink HW, Lawitz EJ , et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013; 368 (18) 1685-1694
  CrossrefPubMedGoogle Scholar
• 74 Paeshuyse J, Kaul A, De Clercq E , et al. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 2006; 43 (4) 761-770
  CrossrefPubMedGoogle Scholar
• 75 Chatterji U, Bobardt M, Selvarajah S , et al. The isomerase active site of cyclophilin A is critical for hepatitis C virus replication. J Biol Chem 2009; 284 (25) 16998-17005
  CrossrefPubMedGoogle Scholar
• 76 Coelmont L, Kaptein S, Paeshuyse J , et al. Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Antimicrob Agents Chemother 2009; 53 (3) 967-976
  CrossrefPubMedGoogle Scholar
• 77 Tiongyip C, Jones CT, Tang Y , et al. Host targeting cyclophilin inhibitor alisporivir presents a high barrier to resistance with no cross-resistance to direct acting antivirals. Abstract presented at: The Sixth International Workshop on Hepatitis C, Resistance and New Compounds; June 23–24, 2011; Cambridge, MA
  PubMedGoogle Scholar
• 78 ClinicalTrials.gov. Pharmacokinetics, pharmacodynamics and safety of DEB025 plus ribavirin in chronic hepatitis C genotype 2 and 3 treatment naïve patients. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01970904?term=cdeb025A2222&rank=1 . Accessed November 18, 2013
  PubMedGoogle Scholar
• 79 Pawlotsky JM, Sarin SK, Foster G , et al. Alisporivir plus ribavirin is highly effective as interferon-free or interferon-add-on regimen in previously untreated HCV-GT2 or GT3 patients: SVR12 results from VITAL-1 phase 2b study. J Hepatol 2012; 56 (2) S553 [1405]
  PubMedGoogle Scholar
• 80 Chatterji U, Wong KA, Zhong W , et al. The Combination of Alisporivir with an NS5A Inhibitor Provides Additive to Synergistic Antiviral Activity, no Cross-Resistance and a High Barrier to HCV Resistance. Hepatology 2013; 58 (4) 62A [74]
  PubMedGoogle Scholar
• 81 Hopkins S, DiMassimo B, Rusnak P , et al. The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection. J Hepatol 2012; 57 (1) 47-54
  CrossrefPubMedGoogle Scholar
• 82 Owens CM, Rhodin MHJ, Polemeropoulos A , et al. Cyclophilin inhibitor EDP-546 is a potential cornerstone drug for use in combination with NS5A and protease inhibitors due to its high barrier to HCV resistance. J Hepatol 2013; 58 (1) S493 . [1213]
  PubMedGoogle Scholar